<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<base href="SBA%203/17/25%202R">
<title>S1192 2R</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Albertus Extra Bold";
	panose-1:2 14 8 2 4 3 4 2 2 4;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 6 4 5 2 3 4;}
@font-face
	{font-family:Albertus;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:AlbertusExtraBold;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	background:navy;
	font-size:12.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:9.0pt;
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
p.FronterPage, li.FronterPage, div.FronterPage
	{mso-style-name:FronterPage;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Para10pt
	{mso-style-name:Para10pt;
	font-family:"Times New Roman",serif;}
p.PrefileFronterTitle, li.PrefileFronterTitle, div.PrefileFronterTitle
	{mso-style-name:PrefileFronterTitle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.StylePrefileFronterTitleLeft, li.StylePrefileFronterTitleLeft, div.StylePrefileFronterTitleLeft
	{mso-style-name:"Style PrefileFronterTitle + Left";
	margin-top:0in;
	margin-right:-.2in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BillHead
	{mso-style-name:BillHead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeading2
	{mso-style-name:BillHeading2;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillLanguage
	{mso-style-name:BillLanguage;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.HangingAnAct, li.HangingAnAct, div.HangingAnAct
	{mso-style-name:HangingAnAct;
	mso-style-link:"HangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.HangingAnActChar
	{mso-style-name:"HangingAnAct Char";
	mso-style-link:HangingAnAct;
	letter-spacing:.2pt;}
span.11ptChar
	{mso-style-name:11ptChar;
	font-family:"Times New Roman",serif;}
span.BillHeadUnBold
	{mso-style-name:BillHeadUnBold;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.bpuBill, li.bpuBill, div.bpuBill
	{mso-style-name:bpuBill;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:26.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuHeadSpon, li.bpuHeadSpon, div.bpuHeadSpon
	{mso-style-name:bpuHeadSpon;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.bpuHeadSponChar
	{mso-style-name:bpuHeadSponChar;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuIntro, li.bpuIntro, div.bpuIntro
	{mso-style-name:bpuIntro;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuLegislature, li.bpuLegislature, div.bpuLegislature
	{mso-style-name:bpuLegislature;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:24.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuNormText, li.bpuNormText, div.bpuNormText
	{mso-style-name:bpuNormText;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuReprint, li.bpuReprint, div.bpuReprint
	{mso-style-name:bpuReprint;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:22.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.bpuSponsor, li.bpuSponsor, div.bpuSponsor
	{mso-style-name:bpuSponsor;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuState, li.bpuState, div.bpuState
	{mso-style-name:bpuState;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:32.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.charMarlett
	{mso-style-name:charMarlett;
	font-family:Marlett;}
p.ElevenPt, li.ElevenPt, div.ElevenPt
	{mso-style-name:ElevenPt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage12pt, li.FronterPage12pt, div.FronterPage12pt
	{mso-style-name:FronterPage12pt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageBillHeading, li.FronterPageBillHeading, div.FronterPageBillHeading
	{mso-style-name:FronterPageBillHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FronterPageNOCAPS, li.FronterPageNOCAPS, div.FronterPageNOCAPS
	{mso-style-name:FronterPageNOCAPS;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times",serif;}
p.FronterPageTBox2, li.FronterPageTBox2, div.FronterPageTBox2
	{mso-style-name:FronterPageTBox2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageTextBox, li.FronterPageTextBox, div.FronterPageTextBox
	{mso-style-name:FronterPageTextBox;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.FronterSameAs, li.FronterSameAs, div.FronterSameAs
	{mso-style-name:FronterSameAs;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Pg2Footer, li.Pg2Footer, div.Pg2Footer
	{mso-style-name:Pg2Footer;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Style10pt
	{mso-style-name:"Style 10 pt";
	font-family:"Times New Roman",serif;}
p.StyleFronterPage11pt, li.StyleFronterPage11pt, div.StyleFronterPage11pt
	{mso-style-name:"Style FronterPage + 11 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.StyleFronterPageLoweredby3pt, li.StyleFronterPageLoweredby3pt, div.StyleFronterPageLoweredby3pt
	{mso-style-name:"Style FronterPage + Lowered by  3 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	position:relative;
	top:3.0pt;}
p.StyleFronterSameAsPatternSolid100White, li.StyleFronterSameAsPatternSolid100White, div.StyleFronterSameAsPatternSolid100White
	{mso-style-name:"Style FronterSameAs + Pattern\: Solid \(100%\) \(White\)";
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Whereas
	{mso-style-name:Whereas;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
p.bpuWpGraphic, li.bpuWpGraphic, div.bpuWpGraphic
	{mso-style-name:bpuWpGraphic;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.LeftBrackt
	{mso-style-name:LeftBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.RightBrackt
	{mso-style-name:RightBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.Superscript
	{mso-style-name:Superscript;
	font-family:"Albertus",sans-serif;
	font-weight:bold;
	vertical-align:super;}
p.sponUdate, li.sponUdate, div.sponUdate
	{mso-style-name:sponUdate;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BoldItal
	{mso-style-name:BoldItal;
	font-weight:bold;
	font-style:italic;}
p.amendfooter, li.amendfooter, div.amendfooter
	{mso-style-name:amendfooter;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.HangingSup, li.HangingSup, div.HangingSup
	{mso-style-name:HangingSup;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableBottom, li.HangingTableBottom, div.HangingTableBottom
	{mso-style-name:HangingTableBottom;
	margin-top:0in;
	margin-right:1.0in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableTop, li.HangingTableTop, div.HangingTableTop
	{mso-style-name:HangingTableTop;
	margin-top:0in;
	margin-right:.5in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 14.0in;
	margin:1.5in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 14.0in;
	margin:1.5in 113.75pt 1.0in 113.75pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:8.5in 14.0in;
	margin:1.0in 1.75in 85.5pt 2.0in;}
div.WordSection3
	{page:WordSection3;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=bpuReprint>[Second Reprint]</p>

<p class=bpuBill>SENATE, No. 1192 </p>

<p class=bpuWpGraphic></p>

<p class=bpuState>STATE OF NEW JERSEY</p>

<p class=bpuLegislature>221st LEGISLATURE</p>

<p class=bpuWpGraphic>  </p>

<p class=bpuIntro>PRE-FILED FOR INTRODUCTION IN THE 2024 SESSION</p>

<p class=bpuIntro>&nbsp;</p>

</div>

<span style='font-size:12.0pt;line-height:120%;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:auto'>
</span>

<div class=WordSection2>

<p class=bpuIntro>&nbsp;</p>

<p class=bpuSponsor>Sponsored by:</p>

<p class=bpuSponsor>Senator  RAJ MUKHERJI</p>

<p class=bpuSponsor>District 32 (Hudson)</p>

<p class=bpuSponsor>Senator  VIN GOPAL</p>

<p class=bpuSponsor>District 11 (Monmouth)</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>Co-Sponsored by:</p>

<p class=bpuSponsor>Senators Johnson, Bramnick, Ruiz, Burgess, Steinhardt and
Wimberly</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>SYNOPSIS</p>

<p class=bpuNormText>     Requires prescription drug coverage for serious
mental illness without prior authorization or utilization management, including
step therapy.</p>

<p class=bpuNormText>&nbsp;</p>

<p class=bpuSponsor>CURRENT VERSION OF TEXT </p>

<p class=bpuNormText>     As reported by the Senate Budget and Appropriations
Committee on March 17, 2025, with amendments.</p>

<p class=bpuNormText>   </p>

</div>

<span style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=HangingAnAct style='line-height:150%'><span class=BillHead>An Act</span><span
class=HangingAnActChar> concerning utilization management, amending P.L.2019,
c.58, and supplementing P.L.1968, c.413 (30:4D-1 et seq.).</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     <span class=BillHeading2>Be It
Enacted </span><span class=BillLanguage>by the Senate and General Assembly of
the State of New Jersey:</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      1.   Section
11 of P.L.2019, c.58 (C.26:2S-10.8) is amended to read as follows:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      11. 
a.  For the purposes of this section:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      &quot;Benefit
limits&quot; includes both quantitative treatment limitations and
non-quantitative treatment limitations. </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      &quot;Carrier&quot;
means an insurance company, health service corporation, hospital service
corporation, medical service corporation, or health maintenance organization
authorized to issue health benefits plans in this State or any entity
contracted to administer health benefits in connection with the State Health
Benefits Program or School Employees' Health Benefits Program.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      &quot;Classification
of benefits&quot; means the classifications of benefits found at 45 C.F.R.
146.136(c)(2)(ii)(A) and 45 C.F.R. s.146.136(c)(3)(iii).</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      &quot;Department&quot;
means the Department of Banking and Insurance.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>&quot;Mental
health condition&quot; means a condition defined to be consistent with
generally recognized independent standards of current medical practice
referenced in the current version of the Diagnostic and Statistical Manual of
Mental Disorders.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      &quot;Non-quantitative
treatment limitations&quot; or &quot;NQTL&quot; means processes, strategies, or
evidentiary standards, or other factors that are not expressed numerically, but
otherwise limit the scope or duration of benefits for treatment. NQTLs shall
include, but shall not be limited to:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (1) Medical
management standards limiting or excluding benefits based on medical necessity
or medical appropriateness, or based on whether the treatment is experimental
or investigative;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2) Formulary
design for prescription drugs;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (3) For
plans with multiple network tiers, such as preferred providers and
participating providers, network tier design;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (4) Standards
for provider admission to participate in a network, including reimbursement
rates;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (5) Plan
methods for determining usual, customary, and reasonable charges;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (6) Refusal
to pay for higher-cost therapies until it can be shown that a lower-cost
therapy is not effective, also known as fail-first policies or step therapy
protocols;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (7) Exclusions
based on failure to complete a course of treatment;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (8) Restrictions
based on geographic location, facility type, provider specialty, and other
criteria that limit the scope or duration of benefits for services provided
under the plan or coverage;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (9) In
and out-of-network geographic limitations;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (10) 
Limitations on inpatient services for situations where the participant is a
threat to self or others;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (11) 
Exclusions for court-ordered and involuntary holds;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (12) 
Experimental treatment limitations;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (13) 
Service coding;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (14) 
Exclusions for services provided by a licensed professional who provides mental
health condition or substance use disorder services;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (15) 
Network adequacy; and</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (16) 
Provider reimbursement rates.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      <u>Serious
mental illness means the following psychiatric illnesses as defined in the
most current version of the Diagnostic and Statistical Manual of Mental
Disorders:</u></span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      <u>(1)</u> </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>schizophrenia, schizo-affective disorders including
bipolar and depressive, and</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><span
style='letter-spacing:0pt'> <u>bipolar disorders including hypomanic, manic,
depressive, and mixed;</u></span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      <u>(2)</u> </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b><u><span
style='letter-spacing:0pt'>depression in childhood and adolescence;</span></u></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      <u>(3)</u></span><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>2</sup></span></b><span
style='letter-spacing:0pt'> <u>major depressive disorders, whether a single
episode or recurrent</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>1</span></sup></b><u><span style='letter-spacing:0pt'>,
including, but not limited to, any major depressive disorder with peripartum
onset</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>1 </span></sup></b><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b><u><span
style='letter-spacing:0pt'>;</span></u></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      <u>(4) obsessive
compulsive disorders;</u></span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      <u>(5) paranoid
and other psychotic disorders;</u></span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      <u>(6) schizo-affective
disorders including bipolar and depressive;</u> </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><u><span
style='letter-spacing:0pt'>and</span></u><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      <u>(7) schizophrenia</u></span><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>2 </sup></span></b><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><u><span
style='letter-spacing:0pt'>; and</span></u></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b><u><span
style='letter-spacing:0pt'>(8)</span></u><b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>(3)</u></span><b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif'>2</span></sup></b><span style='letter-spacing:
0pt'> <u>post-traumatic stress disorder</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><u><span
style='letter-spacing:0pt'>.</span></u></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      &quot;Substance
use disorder&quot; means a disorder defined to be consistent with generally
recognized independent standards of current medical practice referenced in the
most current version of the Diagnostic and Statistical Manual of Mental
Disorders.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      b.   A
carrier shall approve a request for an in-plan exception if the carrier's
network does not have any providers who are qualified, accessible and available
to perform the specific medically necessary service. A carrier shall
communicate the availability of in-plan exceptions: </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (1) on
its website where lists of network providers are displayed; and</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2) to
beneficiaries when they call the carrier to inquire about network providers.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      c.   A
carrier that provides hospital or medical expense benefits through individual
or group contracts shall submit an annual report to the department on or before
March 1. The annual report shall contain, to the extent that the commissioner
determines practicable, the following information:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (1) A
description of the process used to develop or select the medical necessity
criteria for mental health benefits, the process used to develop or select the
medical necessity criteria for substance use disorder benefits, and the process
used to develop or select the medical necessity criteria for medical and
surgical benefits;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2) Identification
of all NQTLs that are applied to mental health benefits, all NQTLs that are
applied to substance use disorder benefits, and all NQTLs that are applied to
medical and surgical benefits, including, but not limited to, those listed in
subsection a. of this section;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (3) The
results of an analysis that demonstrates that for the medical necessity
criteria described in paragraph (1) of this subsection and for selected NQTLs
identified in paragraph (2) of this subsection, as written and in operation,
the processes, strategies, evidentiary standards, or other factors used to
apply the medical necessity criteria and selected NQTLs to mental health
condition and substance use disorder benefits are comparable to, and are no
more stringently applied than the processes, strategies, evidentiary standards,
or other factors used to apply the medical necessity criteria and selected
NQTLs, as written and in operation, to medical and surgical benefits. A
determination of which selected NQTLs require analysis will be determined by
the department; at a minimum, the results of the analysis shall entail the
following, provided that some NQTLs may not necessitate all of the steps
described below:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (a) identify
the factors used to determine that an NQTL will apply to a benefit, including
factors that were considered but rejected;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (b) identify
and define the specific evidentiary standards, if applicable, used to define
the factors and any other evidentiary standards relied upon in designing each
NQTL;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (c) provide
the comparative analyses, including the results of the analyses, performed to
determine that the processes and strategies used to design each NQTL, as
written, for mental health and substance use disorder benefits are comparable
to and applied no more stringently than the processes and strategies used to
design each NQTL as written for medical and surgical benefits;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (d) provide
the comparative analyses, including the results of the analyses, performed to
determine that the processes and strategies used to apply each NQTL, in
operation, for mental health and substance use disorder benefits are comparable
to and applied no more stringently than the processes or strategies used to
apply each NQTL in operation for medical and surgical benefits; and</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (e) disclose
the specific findings and conclusions reached by the carrier that the results
of the analyses above indicate that the carrier is in compliance with this
section and the Paul Wellstone and Pete Domenici Mental Health Parity and
Addiction Equity Act of 2008, 42 U.S.C. s.18031(j), and its implementing and
related regulations, which includes 45 C.F.R. s.146.136, 45 C.F.R. s.147.160,
and 45 C.F.R. s.156.115(a)(3); and </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (4) Any
other information necessary to clarify data provided in accordance with this
section requested by the Commissioner of Banking and Insurance including
information that may be proprietary or have commercial value, provided that no
proprietary information shall be made publicly available by the department.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      d.   The
department shall implement and enforce applicable provisions of the Paul
Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of
2008, 42 U.S.C. 18031(j), any amendments to, and federal guidance or
regulations issued under that act, including 45 C.F.R. Parts 146 and 147, 45
C.F.R. s.156.115(a)(3), P.L.1999, c.106 (C.17:48-6v et al.), and section 2 of
P.L.1999, c.441 (C.52:14-17.29e), which includes:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (1) Ensuring
compliance by individual and group contracts, policies, plans, or enrollee
agreements delivered, issued, executed, or renewed in this State pursuant to
P.L.1938, c.366 (C.17:48-1 et seq.), P.L.1940, c.74 (C.17:48A-1 et seq.),
P.L.1985, c.236 (C.17:48E-1 et seq.), chapter 26 of Title 17B of the New Jersey
Statutes (N.J.S.17B:26-1 et seq.), chapter 27 of Title 17B of the New Jersey
Statutes (N.J.S.17B:27-26 et seq.), P.L.1992, c.161 (C.17B:27A-2 et seq.),
P.L.1992, c.162 (C.17B:27A-17 et seq.), P.L.1973, c.337 (C.26:2J-1 et seq.),
and P.L.1961, c.49 (C.52:14-17.25 et seq.), or approved for issuance or renewal
in this State by the Commissioner of Banking and Insurance.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2) Detecting
violations of the law by individual and group contracts, policies, plans, or
enrollee agreements delivered, issued, executed, or renewed in this State
pursuant to P.L.1938, c.366 (C.17:48-1 et seq.), P.L.1940, c.74 (C.17:48A-1 et
seq.), P.L.1985, c.236 (C.17:48E-1 et seq.), chapter 26 of Title 17B of the New
Jersey Statutes (N.J.S.17B:26-1 et seq.), chapter 27 of Title 17B of the New
Jersey Statutes (N.J.S.17B:27-26 et seq.), P.L.1992, c.161 (C.17B:27A-2 et
seq.), P.L.1992, c.162 (C.17B:27A-17 et seq.), P.L.1973, c.337 (C.26:2J-1 et
seq.), and P.L.1961, c.49 (C.52:14-17.25 et seq.), or approved for issuance or
renewal in this State by the Commissioner of Banking and Insurance.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (3) Accepting,
evaluating, and responding to complaints regarding violations.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (4) Maintaining
and regularly reviewing for possible parity violations a publicly available
consumer complaint log regarding mental health condition and substance use
disorder coverage, provided that the names of specific carriers will be
redacted and not disclosed on the complaint log.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (5) The
commissioner shall adopt rules as may be necessary to effectuate any provisions
of this section and the Paul Wellstone and Pete Domenici Mental Health Parity
and Addiction Equity Act of 2008 that relate to the business of insurance.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      e.   Not
later than May 1 of each year, the department shall issue a report to the
Legislature pursuant to section 2 of P.L.1991, c.164 (C.52:14-19.1). The report
shall:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (1) Describe
the methodology the department is using to check for compliance with the Paul
Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of
2008, 42 U.S.C s.18031(j), and any federal regulations or guidance relating to
the compliance and oversight of that act.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2) Describe
the methodology the department is using to check for compliance with P.L.1999,
c.106 (C.17:48-6v et al.) and section 2 of P.L.1999, c.441 (C.52:14-17.29e).</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (3) Identify
market conduct examinations conducted or completed during the preceding
12-month period regarding compliance with parity in mental health and substance
use disorder benefits under state and federal laws and summarize the results of
such market conduct examinations. This shall include: </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (a) The
number of market conduct examinations initiated and completed;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (b) The
benefit classifications examined by each market conduct examination;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (c) The
subject matters of each market conduct examination, including quantitative and
non-quantitative treatment limitations;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (d) A
summary of the basis for the final decision rendered in each market conduct
examination; and</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (e) Individually
identifiable information shall be excluded from the reports consistent with
state and Federal privacy protections.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (4) Detail
any educational or corrective actions the department has taken to ensure
compliance with Paul Wellstone and Pete Domenici Mental Health Parity and
Addiction Equity Act of 2008, 42 U.S.C s.18031(j), P.L.1999, c.106 (C.17:48-6v
et al.) and section 2 of P.L.1999, c.441 (C.52:14-17.29e).</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (5) Detail
the department's educational approaches relating to informing the public about
mental health condition and substance use disorder parity protections under
State and federal law.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (6) Be
written in non-technical, readily understandable language and shall be made
available to the public by, among such other means as the department finds
appropriate, posting the report on the department's website.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      f.    The
department shall post on its Internet website a report disclosing the
department's conclusions as to whether the analyses collected from the carriers
as specified in paragraph (3) of subsection c. of this section demonstrate
compliance with the Mental Health Parity and Addiction Equity Act of 2008 and
its implementing regulations, specifically including whether or not there is
compliance with 45 C.F.R. 146.136(c)(4). The name and identity of carriers
shall be confidential, shall not be made public by the department, and shall
not be subject to public inspection.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      <u>g.   A
carrier shall provide coverage for a prescription drug prescribed for serious
mental illness to covered persons without the </u></span></p>

<p class=MsoNormal style='line-height:150%'><u><span style='letter-spacing:
0pt'>imposition of any prior authorization or other utilization management
requirements, including, but not limited to, a step therapy protocol.</span></u></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>(cf:
P.L.2019, c.58, s.11)</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     2.    (New section)  a.
Notwithstanding the provisions of any law, rule, or regulation to the contrary,
the division shall provide coverage for prescription drugs to treat serious
mental illness under the Medicaid program and the NJ FamilyCare program without
the imposition of any prior authorization or other utilization management
requirements, including, but not limited to, a step therapy protocol, provided
that the prescription drug is prescribed to an enrollee by a licensed medical
practitioner who is authorized to prescribe that treatment pursuant to State
and federal law.</p>

<p class=MsoNormal style='line-height:150%'>     b.    The division shall
require each managed care organization contracted with the division to provide
pharmacy benefits to Medicaid and NJ FamilyCare enrollees to comply with the
provisions of this section.</p>

<p class=MsoNormal style='line-height:150%'>     c.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Division means the Division
of Medical Assistance and Health Services in the Department of Human Services.</p>

<p class=MsoNormal style='line-height:150%'>     Medicaid program means the
program established pursuant to P.L.1968, c.413 (C.30:4D-1 et seq.).</p>

<p class=MsoNormal style='line-height:150%'>     NJ FamilyCare program means
the program established pursuant to P.L.2005, c.156 (C.30:4J-8 et al.).</p>

<p class=MsoNormal style='line-height:150%'>     Serious mental illness means
the following psychiatric illnesses as defined in the most current version of
the Diagnostic and Statistical Manual of Mental Disorders:</p>

<p class=MsoNormal style='line-height:150%'>     (1)  bipolar disorders
including hypomanic, manic, depressive, and mixed;</p>

<p class=MsoNormal style='line-height:150%'>     (2)  depression in childhood
and adolescence;</p>

<p class=MsoNormal style='line-height:150%'>     (3)  major depressive
disorders, whether a single episode or recurrent<b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif'>1</span></sup></b><u><span style='letter-spacing:
0pt'>, including, but not limited to, any major depressive disorder with
peripartum onset</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>;</p>

<p class=MsoNormal style='line-height:150%'>     (4)  obsessive compulsive
disorders;</p>

<p class=MsoNormal style='line-height:150%'>     (5)  paranoid and other
psychotic disorders;</p>

<p class=MsoNormal style='line-height:150%'>     (6)  schizo-affective
disorders including bipolar and depressive; <b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span style='font-family:
"Albertus Extra Bold",sans-serif'>[</span></b><u>and</u><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'>     <u>(7)  schizophrenia</u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><u><span
style='letter-spacing:0pt'>; and</span></u></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>     <u>(8)  post-traumatic
stress disorder</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><u>.</u></p>

<p class=MsoNormal style='line-height:150%'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=MsoNormal style='line-height:150%'>     3.    This act shall take
effect on the 180th day next following the date of enactment and shall apply to
policies issued or renewed on or after that effective date.</p>

</div>

</body>

</html>
